G1 Therapeutics (GTHX) News Today $3.91 -0.04 (-1.01%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 4:17 PM | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutionsJuly 25 at 11:15 AM | globenewswire.comG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024July 25 at 7:36 AM | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Bought by Acadian Asset Management LLCAcadian Asset Management LLC increased its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 643.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,709 shares of the company's stock after purchasJuly 15, 2024 | investorplace.comG1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025July 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 9, 2024 | insidertrades.comJohn E. (Jack) Jr. Bailey Sells 7,662 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockJuly 1, 2024 | globenewswire.comG1 Therapeutics Added to the Russell 2000® and 3000® IndexesJune 27, 2024 | marketbeat.comFY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of G1 Therapeutics in a note issued to investors on Tuesday, June 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings of (June 25, 2024 | marketbeat.comNeedham & Company LLC Trims G1 Therapeutics (NASDAQ:GTHX) Target Price to $6.00Needham & Company LLC dropped their price target on shares of G1 Therapeutics from $12.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday.June 24, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for G1 Therapeutics (NASDAQ:GTHX)Wedbush reaffirmed an "outperform" rating and issued a $3.00 target price (down previously from $5.00) on shares of G1 Therapeutics in a research report on Monday.June 24, 2024 | marketbeat.comStock Traders Purchase High Volume of Put Options on G1 Therapeutics (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of unusually large options trading activity on Monday. Investors purchased 3,989 put options on the stock. This represents an increase of approximately 97% compared to the typical daily volume of 2,023 put options.June 24, 2024 | investorplace.comWhy Is G1 Therapeutics (GTHX) Stock Down 56% Today?June 24, 2024 | globenewswire.comG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)June 17, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest UpdateG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 4,060,000 shares, an increase of 13.1% from the May 15th total of 3,590,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is presently 3.1 days.June 13, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)Needham & Company LLC reissued a "buy" rating and issued a $12.00 target price on shares of G1 Therapeutics in a report on Thursday.June 5, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Up 26.9% in MayG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,590,000 shares, an increase of 26.9% from the April 30th total of 2,830,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is presently 2.6 days.May 28, 2024 | markets.businessinsider.comBuy Rating Affirmed: G1 Therapeutics’ Cosela Shows Significant Survival Benefits in mTNBCMay 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for G1 Therapeutics Amid Promising Clinical OutcomesMay 28, 2024 | msn.comG1 Therapeutics slips after new breast cancer data for lead assetMay 28, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of G1 Therapeutics in a research report on Tuesday.May 28, 2024 | globenewswire.comMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)May 25, 2024 | insidertrades.comMonica R. Thomas Sells 5,826 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockMay 24, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Sells $24,877.02 in StockG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) insider Monica R. Thomas sold 5,826 shares of G1 Therapeutics stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $4.27, for a total value of $24,877.02. Following the sale, the insider now directly owns 109,825 shares of the company's stock, valued at $468,952.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.May 24, 2024 | markets.businessinsider.comStrategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 TherapeuticsMay 23, 2024 | globenewswire.comG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)May 22, 2024 | finance.yahoo.comG1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitMay 22, 2024 | marketbeat.comG1 Therapeutics' (GTHX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research note on Wednesday.May 22, 2024 | globenewswire.comG1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation SummitMay 22, 2024 | markets.businessinsider.comG1 Therapeutics And Deimos Biosciences In License Deal For Lerociclib For Radioprotective UsesMay 22, 2024 | globenewswire.comG1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesMay 16, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Sees Significant Increase in Short InterestG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,830,000 shares, a growth of 16.9% from the April 15th total of 2,420,000 shares. Based on an average trading volume of 1,140,000 shares, the short-interest ratio is currently 2.5 days.May 9, 2024 | msn.comG1 Therapeutics jumps amid takeover speculationMay 9, 2024 | msn.comWhat's Going On With G1 Therapeutics Stock?May 4, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 3, 2024 | marketbeat.comFY2026 EPS Estimates for G1 Therapeutics, Inc. Reduced by HC Wainwright (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of G1 Therapeutics in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the company wilMay 3, 2024 | finance.yahoo.comG1 Therapeutics First Quarter 2024 Earnings: Revenues DisappointMay 2, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPSG1 Therapeutics (NASDAQ:GTHX - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. During the same period in the previous year, the company posted ($0.53) EPS.May 2, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for G1 Therapeutics (NASDAQ:GTHX)HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of G1 Therapeutics in a research note on Thursday.May 2, 2024 | markets.businessinsider.comOptimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela’s Market ExpansionMay 2, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...May 1, 2024 | finance.yahoo.comQ1 2024 G1 Therapeutics Inc Earnings CallMay 1, 2024 | markets.businessinsider.comEvaluating G1 Therapeutics: Insights From 5 Financial AnalystsMay 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comGTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | msn.comG1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue ProjectionsMay 1, 2024 | globenewswire.comG1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Next opportunity for crypto millions (Ad)The Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now… Check out the new "Crypto Bull Run Millionaire Blueprint" now! GTHX Media Mentions By Week GTHX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼0.760.62▲Average Medical News Sentiment GTHX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼52▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RIGL News Today ZYME News Today ARCT News Today RGNX News Today KALV News Today CGC News Today CTNM News Today ESPR News Today AVXL News Today EDIT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.